Author

S. Buglioni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Pandey· 1 shared B. Dufrusine· 1 shared C. A. Amoreo· 1 shared C. Cristofoletti· 1 shared C. Leonetti· 1 shared D. Giannarelli· 1 shared D. Lamberti· 1 shared E. H. Calvo Roitberg· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Pandey

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer

F. A. Rossi, J. H. Enrique Steinberg, E. H. Calvo Roitberg, M. Joshi, A. Pandey, M. Abba, B. Dufrusine, S. Buglioni, V. De Laurenzi, G. Sala, R. Lattanzio, J. M. Espinosa, M. Rossi

This study identifies USP19 as a regulator of cancer cell migration and invasion, showing its role as a prognostic marker in early breast cancer.

bioRxiv · Jul 1, 2020Cancer Biology

FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling

G. Cristinziano, M. Porru, D. Lamberti, S. Buglioni, F. Rollo, C. A. Amoreo, I. Manni, D. Giannarelli, C. Cristofoletti, G. Russo, M. J. Borad, G. L. Grazi, M. G. Diodoro, S. Giordano, M. Forcato, , O. Segatto

This paper develops FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma and shows that Erk signaling is essential for tumor growth, with double blockade of FF-Ras-Erk pathways improving therapeutic efficacy.

bioRxiv · May 20, 2020 · PreprintCancer Biology